About Kinnate Biopharma
Kinnate Biopharma is a company based in San Diego (United States) founded in 2018 by Eric Murphy and Steve Kaldor was acquired by XOMA Corporation in February 2024. Kinnate Biopharma has raised $172.5 million across 2 funding rounds from investors including Fidelity Investments, Citadel and Orbimed. The company has 30 employees as of December 31, 2020. Kinnate Biopharma operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 30 as on 31 Dec, 2020
- Founders Eric Murphy, Steve Kaldor
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kinnate Biopharma Inc.
-
Annual Revenue
Not available
-
Net Profit
-$112.65 M (USD)3as on Dec 31, 2023
-
EBITDA
-$121.18 M (USD)-2as on Dec 31, 2023
-
Total Equity Funding
$172.5 M (USD)
in 2 rounds
-
Latest Funding Round
$98 M (USD), Series C
Jul 21, 2020
-
Investors
Fidelity Investments
& 14 more
-
Employee Count
30
as on Dec 31, 2020
-
Acquired by
XOMA Corporation
(Feb 16, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Kinnate Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Kinnate Biopharma
Kinnate Biopharma has successfully raised a total of $172.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $98 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kinnate Biopharma
Kinnate Biopharma has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Citadel and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Multiple sectors are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Kinnate Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kinnate Biopharma
Investment portfolio details for Kinnate Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kinnate Biopharma
Detailed financials for Kinnate Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kinnate Biopharma Comparisons
Peer comparison for Kinnate Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kinnate Biopharma
Kinnate Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Kinnate Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kinnate Biopharma
Complete news archive for Kinnate Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kinnate Biopharma
Kinnate Biopharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Kinnate Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Steve Kaldor is the current CEO of Kinnate Biopharma. They have also founded this company.
Kinnate Biopharma is a funded company, having raised a total of $172.5M across 2 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Kinnate Biopharma is 30.
Kinnate Biopharma was founded in 2018 and is headquartered in San Diego, United States. Small molecule therapeutics are developed for cancer treatment within the biopharmaceutical sector. Operations center on three programs: precision oncology targeting DNA damage repair mechanisms, inhibitors addressing gene rearrangements with known resistance mutations, and inhibitors for a pathway validated clinically across various cancers.
Kinnate Biopharma's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Kinnate Biopharma has 15 investors. Key investors include Fidelity Investments, Citadel, Orbimed, Janus Henderson Investors, and RA Capital.